Please visit novavax.com and LinkedIn for more information. You are encouraged to read our filings with the SEC, available at www.sec.govand www.novavax.com, for a discussion of these and other risks and uncertainties. July 13 (Reuters) - The U.S. Food and Drug Administration authorized the use of Novavax Inc's (NVAX.O) COVID-19 vaccine on Wednesday, clearing the way for a shot whose more traditional. The vaccine contains the SARS-CoV-2 spike protein and Matrix-M adjuvant. A webcast of the conference call can also be accessed on the Novavax website at novavax.com/events. older adults, persons with moderate to severe immunocompromising conditions, and health workers) should be offered it first. Other protein-based Covid vaccines are also in late-stage clinical trials, including one being developed by Sanofi and GSK, again with 60m orders from the UK. Statements herein relating to the future of Novavax, its near term priorities including delivering an updated vaccine for the 2023 fall vaccination season, streamlining its investment and organizational structure and building value for Novavax from its technology platform and Matrix-M adjuvant, its operating plans, objectives and prospects, including Novavax's ability to continue as a going concern within one year after the issuance date of the financial statements for the year ended December 31, 2022, its anticipated strategic plan, its future financial or business performance, conditions or strategies, its partnerships, the timing of clinical trial results, the ongoing development of NVX-CoV2373, and a bivalent or monovalent Omicron-based / original strain based vaccine, the CIC investigational vaccine candidate, a quadrivalent influenza investigational vaccine candidate, the scope, timing and outcome of future and pending regulatory filings and actions and additional worldwide authorizations of NVX-CoV2373 for use in adults and adolescents and as a booster, are forward-looking statements. The Novavax jab has already been approved for use in the Philippines and Indonesia. On Jan. 31, Novavax formally submitted its request to the Food and Drug Administration (FDA) to have its COVID-19 vaccine approved for EUA. The JCVI's chair of Covid-19, Professor Wei Shen Lim, says only that the vaccine's potential use remains "under consideration" and full advice will be published in "due course". As of 26 August 2022, Nuvaxovid has not been deployed in the UKs COVID-19 vaccination programme. The trial will assess a CIC vaccine comprised of Novavax's recombinant protein-based COVID-19 vaccine, quadrivalent influenza vaccine candidate, and patented saponin-based Matrix-M adjuvant. Meanwhile, Novavax got its first approval anywhere in the world on Monday, when the company and partner Serum received emergency-use authorization for their COVID-19 vaccine in Indonesia.
novavax covid vaccine approval date